
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
One change is the repeal of the requirement that professionals obtain patients' written consent for disclosing information, payment, or other purposes